Plecanatide: Phase III started

Synergy began a 12-week, double-blind, placebo-controlled, U.S. Phase III trial to evaluate once-daily 3 and 6 mg oral plecanatide in about 1,050 patients. Data from the trial are expected in 4Q15. Th...